Dr. Li's research focuses on the mechanisms and targeting of residual tumors following chemotherapy and/or targeted therapy, with the ultimate goal of preventing tumor recurrence. Dr. Li completed his medical education at Beijing Medical University and received his graduate training at Penn State. Dr. Li then pursued postdoctoral research at Stanford University before joining the Research Institute. His work has been supported by the NIH/NCI, the American Cancer Society (ACS), and the Cancer Prevention and Research Institute of Texas (CPRIT). He is also an American Cancer Society Research Scholar.